# The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

> **NCT02733107** · PHASE2 · UNKNOWN · sponsor: **Third Military Medical University** · enrollment: 25 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT02733107
- **Lead sponsor:** Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2016-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733107, "The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02733107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*